Fibroblast growth factor 23, mineral metabolism and mortality among elderly men

Background: Fibroblast growth factor 23 (FGF23) is the earliest marker of disturbed mineral metabolism as renal function decreases. Its serum levels are associated with mortality in dialysis patients, persons with chronic kidney disease (CKD) and prevalent cardiovascular disease (CVD), and it is associated with atherosclerosis, endothelial dysfunction and left ventricular hypertrophy in the general population. The primary aim of this study is to examine the association between FGF23 and mortality, in relation to renal function in the community. A secondary aim is to examine the association between FGF23 and CVD related death. Methods: The population-based cohort of MrOS Sweden included 3014 men (age 69 – 81 years). At inclusion intact FGF23, intact parathyroid hormone (PTH), 25 hydroxyl vitamin D (25D), calcium and phosphate were measured. Mortality data were collected after an average of 4.5 years follow-up. 352 deaths occurred, 132 of CVD. Association between FGF23 and mortality was analyzed in quartiles of FGF23. Kaplan-Meier curves and Log-rank test were used to examine time to events. Cox proportional hazards regression was used to examine the association between FGF23, in quartiles and as a continuous variable, with mortality. The associations were also analyzed in the sub-cohort with estimated glomerular filtration rate (eGFR) above 60 ml/min/1.73 m 2 . Results: There was no association between FGF23 and all-cause mortality, Hazard ratio (HR) 95% confidence interval (CI): 1.02 (0.89-1.17). For CVD death the HR (95% CI) was 1.26 (0.99 - 1.59)/(1-SD) increase in log(10)FGF23 after adjustment for eGFR, and other confounders. In the sub-cohort with eGFR > 60 ml/min/1.73 m 2 the HR (95% CI) for CVD death was 55% (13 – 111)/(1-SD) increase in log(10)FGF23. Conclusions: FGF23 is not associated with mortality of all-cause in elderly community living men, but there is a weak association with CVD death, even after adjustment for eGFR and the other confounders. The association with CVD death is noticeable only in the sub-cohort with preserved renal function.

[1]  B. Kestenbaum,et al.  Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). , 2012, Journal of the American College of Cardiology.

[2]  J. Kanis,et al.  Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden , 2012, Osteoporosis International.

[3]  A. Cheung,et al.  FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. , 2011, Journal of the American Society of Nephrology : JASN.

[4]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[5]  E. Rimm,et al.  Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. , 2011, American heart journal.

[6]  D. Fliser,et al.  FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  L. Holmberg,et al.  Plasma vitamin D and mortality in older men: a community-based prospective cohort study. , 2010, The American journal of clinical nutrition.

[8]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[9]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[10]  S. Bandinelli,et al.  Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults , 2009, European Journal of Clinical Nutrition.

[11]  H. Melhus,et al.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. , 2009, Atherosclerosis.

[12]  Markku Heliövaara,et al.  American Journal of Epidemiology Original Contribution Vitamin D Status and the Risk of Cardiovascular Disease Death , 2022 .

[13]  L. Lind,et al.  Relationship between circulating FGF23 and total body atherosclerosis in the community. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  L. Lind,et al.  Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. , 2009, Atherosclerosis.

[15]  C. Held,et al.  Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community , 2009, Circulation.

[16]  Thomas J. Wang,et al.  Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.

[17]  M. Stridsberg,et al.  Regulation of fibroblast growth factor-23 in chronic kidney disease. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  L. Hansson,et al.  Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin C values in mg/L , 2007, Scandinavian journal of clinical and laboratory investigation.

[19]  M. Pfeffer,et al.  Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.

[20]  M. Wolf,et al.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  E. Ingelsson,et al.  Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. , 2013, Kidney international.

[22]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .